Synthetic Genistein for the therapy of menopausal syndrome

Abstract

Aim. The purpose of the study is to evaluate the efficacy and safety of synthetic genistein in the treatment of menopausal symptoms in peri-and post-menopausal women.

Material and methods. The investigation enrolled 23 women with menopausal syndrome whose severity was evaluated in accordance with modified menopausal  index (MMI). All the patients received synthetic genistein in a daily dose of 60 mg for 6 months. Its efficacy  wale valuated from the changes in MMI, autonomic dysfunction, and quality of life; its safety was assessed from physical examination results, biochemical markers of liver function, and small pelvic, abdominal, and breast ultrasound findings.

Results of research. Genistein showed a high efficacy in correcting mild and moderate menopausal disorders. After  6 months of therapy, there was a statistically significant (p<0,005) decrease in MMI, from 47,8 to 17,3%.

At the same time, there was a reduction in the mean index of autonomic dysfunction from 41,4±8,3 to 23,6±6,4 (p˂0,005) a positive health changes, as shown by the MOS SF-36 question-naire.

Conclusion. Synthetic genistein (menoril) may be  considered as the drug of choice in treating the neuroautonomic manifestations of mild and moderate menopausal syndrome.